Exelixis

210 East Grand Avenue, South San Francisco, CA 94080

Public
Healthcare & Pharmaceuticals - Pharmaceuticals
around $20 - 50M
around 250 - 500
(650) 837-7000
(650) 837-8300
info@exelixis.com


Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.... (Source: SEC reports)


Competitor - 1/9
Which company is more competitive with Exelixis?


235 Contacts at this company
Anna Lam
Senior Clinical Supplies Manager
Sandra Wiejowski
Executive Director, Medical Affairs ...
Dana Close
Executive Oncology Account Manager
Evan Blander
Vice President, Drug Safety
David Blackett
Director Quality Assurance
Charlotte Furey
Director, Clinical Data Management ...
Yifah Yaron
Senior Medical Director, Clinical
Khalid Shah Ph.D.
Vice President Pharmaceutical ...
Cathi Bartice
Sr. Recruiter, Consultant

Sep 21, 2018 19:18:57
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a  [...]

Sep 21, 2018 17:30:58
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a  [...]

Sep 19, 2018 19:18:36
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen  [...]

Sep 19, 2018 17:30:33
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen  [...]

Sep 7, 2018 19:19:09
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that the National Comprehensive  [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.